2004: Which HIV-1 drug resistance mutations are common in clinical practice?

AIDS Reviews

Volumn 6, Issue 2, 2004, Pages 107-116

  Cheung, Peter K ^a   Wynhoven, Brian ^a   Harrigan, P Richard ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE   (Canada)

Author keywords

Antiretroviral therapy; Drug resistance; HIV; Mutations

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NEW DRUG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; CANADA; CLINICAL PRACTICE; CROSS RESISTANCE; DRUG CHOICE; DRUG USE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREVALENCE; REVIEW; TREATMENT FAILURE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; POINT MUTATION; PREVALENCE;

EID: 4344683266     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Zaccarelli M, Perno C, Forbici F, et al. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antivir Ther 2003;8:51-6.
2. Clotet B, Ruiz L, Martínez-Picado J, Negredo E, Hill A, Popescu M. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials 2002;3:316-23.
3. Harrigan P, Dong W, Alexander C, et al. The association between drug resistance and adherence determined by two independent methods in a large cohort of drug-naive individuals starting triple therapy. 21d IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 13-16, 2003 [abstract LB12],
4. Hirsch M, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with HIV type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-28,
5. Richman D, Morton S, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-401.
6. International AIDS Society (IAS) USA. http://www.iasusa.org.
7. Los Alamos HIV Sequence Database. http://hiv-web.lanl.gov
8. Stanford HIV Drug Resistance Database. http://hivdb.stanford.edu
9. HIV Resistance web. http://www.resistanceweb.com
10. Kuiken C, Korber B, Shafer R. HIV sequence databases. AIDS Rev 2003;5:52-61.
11. Gonzales M, Wu T, Taylor J, et al, Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003;17:791-9.
12. Wu T, Schiffer C, Gonzales M, at al. Mutation patterns and structural correlates in HIV type 1 protease following different protease inhibitor treatments. J Virol 2003;77:4836-47.
13. Chen L, Perlina A, Lee C. Positive selection detection in 40,000 HIV type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. J Virol 2004;78:3722-32,
14. Deeks S. Treatment of antiretroviral drug-resistant HIV-1 infection. Lancet 2003;362:2002-11.
15. Johnson V, Brun-Vezinet F, Clotet B, et al. IAS-USA Drug Resistance Mutations Group. Drug resistance mutations in HIV-1. Top HIV Med 2003;11:215-21.
16. Gallant J, Gerondelis P, Wainberg M, et al, Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antiviral Ther 2003;8:489-506.
17. Fumero E, Podzamczer D. New patterns of HIV-1 resistance during HAART. Clin Microbiol Infect 2003;9:1077-84.
18. Patarca R, Isava A, Campo R, et al. HIV-1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (part 2). J Environ Pathol Toxicol Oncol 2003;22:235-79.
19. Kantor R, Katzenstein D. Drug resistance in non-subtype BHIV-1. J Clin Virol 2004;29:152-9.
20. Kantor R, Katzenstein D, Camacho R, et al. Genotypic analyses of FIT and protease sequences from persons infected with non-subtype B HIV-1. 101h Conference on Retrovinuses and Opportunistic Infections. Boston, MA, February 10-14, 2003 [abstract 623].
21. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of HIV type 1 found in Brazilian patients failing HAART. Virus Genes 2001;23:193-202.
22. Cane P, Osman H, Smit E. Effect of HIV-1 subtype on development of NNRTI resistance mutations in patients failing first line therapy. XIII International HIV Drug Resistance Workshop. Tenerife, June 8-12, 2004 [abstract 104]. Antiviral Ther 2004;9:115.
23. Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
24. British Columbia Centre for Excellence in HIVADS. The HIVAIDS Drug Treatment Program, Status Report. January 2003.
25. Larder B, Kemp S, Harrigan P, Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-9.
26. Boucher C, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of HIV type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
27. Schuurman R, Nijhuis M, Van Leeuwen R, et al. Rapid changes in HIV type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:1411-9.
28. Zaccarelli M, Perno C, Forbici F, et al. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis 2004;38:433-7.
29. Matsumi S, Kosalaralksa P, Tsang H, Kavlick M, Harada S, Mitsuya H. Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants. AIDS 2003;17:1127-37.
30. Meyer P, Lennerstrand J, Matsuura S, Larder B, Scott W. Effects of dipeptide insertions between codons 69 and 70 of HIV type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J Virol 2003;77:3871-7.
31. Miller M, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil furnarate treatment in anti retroviral-experienced patients. J Infect Dis 2004; 189:837-46.
32. Roge B, Katzenstein T, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 2003;8:173-82.
33. White K, Margot N, Wrin T, Petropoulos C, Miller M, Naeger L. Molecular mechanisms of resistance to HIV type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-46.
34. Sirivichayakul S, Ruxrungtham K, Ungsechapand C, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 2003;17:1889-96.
35. Gallego 0, De Mendoza C, Labarga P, et al. Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes. HIV Clin Trials 2003;4:372-81.
36. Quirós-Roldán E, Moretti F, Airoldi M, et al. Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multi-experienced patients. J Clin Lab Anal 2001;15:127-30.
37. Hogg R, Yip B, Chan K, et al, Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
38. Wu T, Schiffer C, Gonzales M, et al. Mutation patterns and structural correlates in HIV type 1 protease following different protease inhibitor treatments. J Virol 2003;77:4836-47.
39. Kagan R, Winters M, Merigan T, Heseltine P. Large-scale cluster analysis of HIV-1 protease mutations in a clinical database. XIII International HIV Drug Resistance Workshop. Tenerife, June 8-12, 2004 [abstract 81]. Antiviral Ther 2004;9:81.
40. Parkin N, Petropoulos C, Chappey C, et al. Isolated lopinavir resistance after virological rebound of a lopinavir/ritonavir based regimen. XIII International HIV Drug Resistance Workshop. Tenerife, June 8-12, 2004 [abstract 70]. Antiviral Ther 2004;9:79.
41. Miller V, Ait-Khaled M, Stone C, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to FIT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000;14:163-71,
42. Winters M, Shafer R, Jellinger R, et al. HIV-1 FIT genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chernother 1997;41:757-62.
43. Margot N, Isaacson E, McGowan 1, Cheng A, Miller M. Extended treatment with tenofovir disoproxil furnarate in treatment-experienced patients: genotypic, phenotypic and rebound analyses. J Acquir Immun Def Syndr 2003;33:15-21.
44. Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A. The prevalence and determinants of the K65R mutation in HIV-1 RT in tenofovir-naive patients. AIDS 2002;16:2087-9.
45. Miller M. K65R, thymidine analogue mutations and tenofovir. AIDS Rev 2004;6:22-33.
46. Winston A, Pozniak A, Mandalia S, Gazzard B, Piliay D, Nelson M. Which nucleoside and nucleotice backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004;18:949-51.
47. MacArthur R, Crane L, Álvarez D, Fairfax M, Richmond D, Curtis G. Factors associated with selection of the K65R mutation: a retrospective chart review. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 13-16, 2003 [abstract 835].
48. Parikh N, Bacheler L. Prevalence, mechanism of resistance and mutational interactions in reviewing the VIRCO database. 1 1th CROI. San Francisco 2004 [abstract 54].
49. Trotta M, Bonfigli S, Ceccherinie F, et al. Clinical and genotypic correlates of K65R mutation in an unselected cohort of HIV-infected persons naive for tenofovir. XIII International Drug Resistance Workshop. Tenerife, June 8-12, 2004 [abstract 152]. Antiviral Ther 2004;9:168.
50. García-Lerma J, MacInnes H, Bennett D, et al. A novel genetic pathway of HIV type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77:5685-93.
51. Podzamczer D, Ferrer E, Gatell J, et al. Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. XIII International HIV Drug Resistance Workshop. Tenerife, June 8-12, 2004 [abstract 1561. Antiviral Ther 2004;9:172
52. Bee A, Waters J, Margot N, Borroto-Esoda K, Miller M, Pre-existing L74V is a risk factor for virological non-response and development of K65R in patients taking tenofovir DF (TDF). XIII International HIV Drug Resistance Workshop. Tenerife, June 8-12, 2004 [abstract 158 Antiviral Ther 2004;9:174.
53. Underwood M, Ross L, Irlbeck D, et al. Sensitivity of phenotypic analyses for detection of K65R or M 1 84V in mixtures with wild-type HIV-1. XIII International HIV Drug Resistance Workshop, Tenerife, June 8-12, 2004 [abstract 130]. Antiviral Ther 2004;9:144.